MT Newswires
RBC Raises Price Target on Fulcrum Therapeutics to $10 From $7, Keeps Sector Perform, Speculative Risk
📊
AI Sentiment
Positive
6/10
- Home
- FULC
as of 12-09-2025 4:00pm EST
$14.60
+$1.60
+12.31%
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Chart Type:
Time Range:
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 468.1M | IPO Year: | 2019 |
| Target Price: | $15.88 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.31 - $15.74 | Next Earning Date: | 10-29-2025 |
| Revenue: | N/A | Revenue Growth: | 2752.05% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered FULC Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 78.91%
78.91%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Fulcrum Therapeutics Inc. (FULC)
Gould Robert J
Sell
Director
FULC Nov 19, 2025
Avg Cost/Share
$11.03
Shares
15,000
Total Value
$165,495.00
Owned After
484,864
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Gould Robert J | FULC | Director | Nov 19, 2025 | Sell | $11.03 | 15,000 | $165,495.00 | 484,864 |
Latest Fulcrum Therapeutics Inc. News
FULC Breaking Stock News: Dive into FULC Ticker-Specific Updates for Smart Investing
MT Newswires
Fulcrum Therapeutics Reports Positive Initial Results from Trial of Pociredir in Sickle Cell Disease; Shares Surge Pre-Bell
📊
AI Sentiment
Positive
7/10
GlobeNewswire
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
📊
AI Sentiment
Positive
6/10
Compare FULC vs Leading Stocks
See how FULC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "FULC Fulcrum Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.